Nucleic Acid Therapeutics

About This Journal:

  • Print This Page
  • Subscribe to an RSS Feed

Sample Content

My Liebert Connect

Sign up to stay informed--receive email notifications for this journal

Nucleic Acid Therapeutics

formerly Oligonucleotides

Co-Editors-in-Chief: Bruce A. Sullenger, PhD
and Annemieke Aartsma-Rus, PhD

Executive Editor
: Graham C. Parker, PhD

ISSN: 2159-3337 • Online ISSN: 2159-3345 • Published Bimonthly

Current Volume: 28

Latest Impact Factor* is 2.338

*2016 Journal Citation Reports® (Clarivate Analytics, 2017)

Aims & Scope

Featured Press Releases and Editorial Content

  • New Method Stabilizes siRNAs Without Affecting Gene Silencing Activity...Read More
  • Oligonucleotide Drug Producers Coauthor Report on Drug Impurities in Nucleic Acid Therapeutics...Read More
  • Modifying Therapeutic DNA Aptamers to Keep Them in the Bloodstream Longer...Read More
  • What's the Next Step for Exon Skipping Therapies to Treat Duchenne Muscular Dystrophy?...Read More
  • Unraveling the Mechanism of Antisense Oligonucleotides--Research from the Crooke Lab...Read More

Aims & Scope

Nucleic Acid Therapeutics is the leading journal in its field focusing on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The Journal examines many new approaches for using nucleic acids as therapeutic agents or in modifying nucleic acids for therapeutic purposes including: oligonucleotides, gene modification, aptamers, RNA nanoparticles, and ribozymes.  

Nucleic Acid Therapeutics coverage includes:

  • RNAi: siRNAs, shRNAs, and miRNAs
  • Antisense applications; nucleoside and nucleotide analogs and modifications
  • Peptide nucleic acids
  • DNA-modified gene therapy
  • Nucleic acid-based nanoparticles
  • Ethical, legal, and regulatory issues

Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center and Annemieke Aartsma-Rus, PhD, Leiden University Medical Center; Executive Editor Graham C. Parker, PhD; and other leading investigators. View the entire editorial board.  

Audience: Molecular biologists, biochemists, DNA and cell biologists, and biopharmaceutical researchers, among others.  

Nucleic Acid Therapeutics is a rapid-publication Journal, with peer review averaging 25 days from submission to first decision, and online publication of the article within four weeks of acceptance.

Society Affiliation

OTSThe Official Journal of Oligonucleotide Therapeutics Society (OTS).

Indexed/Abstracted in:

MEDLINE; PubMed; PubMed Central; Current Contents®/Life Sciences; Science Citation Index Expanded; Social Sciences Citation Index®; Biotechnology Citation Index®; Biological Abstracts; BIOSIS Previews; Journal Citation Reports/Science Edition; Derwent Drug File; EMBASE/Excerpta Medica; EMBiology; Scopus; ProQuest databases

Come See Us!

Show more events...

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Recommended Publications

You may be interested in the following publications:

    Human Gene Therapy

    Human Gene Therapy

    The definitive rapid-publication journal covering all aspects of gene therapy through original investigations into the transfer and expression of genes in mammals, with in-depth coverage of DNA, RNA, and cell therapies.

    Genetic Testing and Molecular Biomarkers

    Genetic Testing and Molecular Biomarkers

    Covers all areas of molecular, biochemical, and clinical genetic testing; ethical, legal, social, and economic aspects of genetic testing; issues concerning effective genetic counseling; and molecular biomarkers.

    DNA and Cell Biology

    DNA and Cell Biology

    Combining mechanistic and clinical studies from multiple systems in a single resource, the Journal delivers authoritative, peer-reviewed reporting on the latest research in the field of molecular biology.

    ASSAY and Drug Development Technologies

    ASSAY and Drug Development Technologies

    This authoritative, rapidly peer-reviewed journal features original articles, application-oriented technology reviews, and reports in methodology and technology application.

Browse All Publications »